Strict Classic Ketogenic Diet as a Therapy for Recurrent or Progressive and Refractory Brain Tumors in Children
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Jul 2024
- Expected to end
- Jan 2027
- Type of study
- Interventional
- Treatments tested
- Strict Classic Ketogenic Diet
- Record updated
- 22 May 2024
- Why it stopped
- Lack of funding for this study.
Who can take part
- Age
- Up to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Age: Patients must be < 21 years of age inclusive at the time of enrollment on this protocol
- Histologic Diagnosis: Histologically proven, primary brain tumor that is recurrent or progressive and refractory (nonresponsive) to standard, accepted therapy. A histopathologic diagnosis from either the initial presentation or at the time of recurrence is required for all subjects, except for diffuse intrinsic pontine glioma (DIPG)
- Measurable Disease: Patients must have radiographically documented measurable tumor as assessed by RANO or RAPNO criteria
- Cranial and Spinal MRI: To document the degree of residual tumor, all patients must have an MRI of the brain with and without gadolinium performed within 2 weeks prior to study enrollment. For patients who undergo a tumor debulking surgery at the time of recurrence/progression, the following must be obtained:
- Cranial pre-operative MRI scan with and without contrast
- Cranial post-operative MRI scan with and without contrast within 28 days following surgery. If possible, post-operative MRI should be performed within 48 hours of surgery, prior to the onset of edema or post-operative surgical enhancement, which can make measurements of residual tumor difficult
- Performance Level: Patients must have a performance status of > 50. Use Karnofsky score for patients > 16 years of age and Lansky score for patients ≤ 16 years of age
- Life Expectancy: Patients must have a life expectancy of > 8 weeks
- Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, biologic therapy, or radiotherapy prior to entering this study
- Growth factor(s): Must not have received within 1 week prior to entry onto this study
- Other anti-cancer or experimental agents or therapies are not permitted. Homeopathic medicines are not permitted. Multivitamins are permitted
- Organ Function Requirements: Adequate bone marrow, renal, liver, pulmonary, and central nervous system function
- All patients and/or their parents or legal guardians must sign a written informed consent
- In the investigator's opinion, patients must have the ability to adhere to or tolerate the dietary protocol
- Patients must be able to eat by mouth or must be willing to have a nasogastric tube (NGT) if gastrostomy tube is not already present
Who cannot take part
- Pregnant or breastfeeding. Female patients of childbearing potential must have negative pregnancy test result within the previous 14 days
- The following medications are excluded: Steroids: Therapeutic systemic doses of steroids must be stopped greater than 2 weeks prior to admission to the hospital to start the diet. A steroid washout of 1 week is acceptable for patients with DIPG. Concomitant chemotherapy drugs and homeopathic drugs are not permitted
- Other Exclusionary Criteria: Disorder of B-oxidation, as measured by plasma aceyl-carnitine, Uncontrolled infection, History of nephrolithiasis, Diagnosis of diabetes mellitus that is being treated by medication
- Pregnancy
- Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
Where in United States
- The University of Texas Southwestern Medical CenterDallas, United States
About the trial
What the trial wants to find out
This is a pilot study to test the feasibility of implementing a strict classic ketogenic diet among a population of children with recurrent or progressive and refractory brain tumors. Eligible participants will be admitted to the neurosciences floor for 5 days to begin the ketogenic diet either orally, by gastrostomy tube or via nasogastric tube. During the inpatient stay, they will be extensively educated on the diet restrictions and rules. Participants will then continue on the diet at home returning about 17 times over the next 12 months. Daily logs will be kept tracking diet changes, bowel movements and urine ketones. Blood will be collected during the inpatient stay and at all visits for both standard clinical care and research testing.
The group in the trial
- Strict Classic Ketogenic Diet ArmOther group
The classic ketogenic diet is individually calculated for each patient based on age, weight, and nutritional needs. The diet is typically administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates. The basis of calculations is first on the amount of required protein needed to meet RDA to insure adequate growth. Fine tuning of ketogenic diet therapy is based on serum beta-hydroxybutyrate levels (target levels of 3.5-6.5 mmol/L), tolerance of the diet, and response to treatment.
Treatment: Strict Classic Ketogenic Diet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of a Strict Classic Ketogenic Diet as a Therapy for Recurrent or Progressive and Refractory Brain Tumors in Children
- Record updated
- 22 May 2024